Recombinant Haemophilus influenzae UPF0208 membrane protein CGSHiEE_06015 (CGSHiEE_06015)

How to ensure proper folding and solubility of recombinant CGSHiEE_06015 during heterologous expression?

Recombinant expression of membrane proteins like CGSHiEE_06015 requires optimization of expression systems and solubilization protocols:

• Host system selection: E. coli remains the default due to cost-effectiveness, but its limitations in post-translational modifications necessitate alternative systems (e.g., yeast or mammalian cells) for proteins requiring eukaryotic folding machinery .

• Solubility tags: Use dual-affinity tags (e.g., His-SUMO) to enhance solubility while minimizing interference with native conformation .

• Detergent screening: Systematic testing of detergents (e.g., n-dodecyl-β-D-maltoside) during extraction improves stability. A comparative analysis of micelle-forming detergents is shown below:

Data adapted from membrane protein purification protocols .

What validation methods confirm the structural integrity of purified CGSHiEE_06015?

Multi-modal validation is critical:

• Circular dichroism (CD) spectroscopy: Compare α-helical content against computational predictions (e.g., PSIPRED). Discrepancies ≥15% indicate misfolding .

• Size-exclusion chromatography (SEC): A monodisperse elution profile with a retention volume matching theoretical molecular weight (24.3 kDa for CGSHiEE_06015) confirms proper oligomerization .

• Surface plasmon resonance (SPR): Binding kinetics to known ligands (e.g., monoclonal antibodies) validate functional epitopes .

How to resolve contradictions between predicted and observed antigenic epitopes in CGSHiEE_06015?

Discrepancies often arise from:

• Conformational vs. linear epitopes: Computational tools (e.g., DiscoTope) predict conformational epitopes, while ELISA/Western blot detect linear sequences .

• Post-translational modifications: Phosphorylation or glycosylation in native H. influenzae may alter epitope accessibility absent in recombinant forms .

Resolution workflow:

• Perform comparative immunoblotting using antisera raised against recombinant vs. native protein.

• Employ hydrogen-deuterium exchange mass spectrometry (HDX-MS) to map solvent-accessible regions.

• Validate with X-ray crystallography (resolution ≤3.0 Å) or cryo-EM for epitope visualization .

What experimental designs minimize confounding variables in CGSHiEE_06015 functional assays?

Adapt principles from robust experimental design frameworks :

• Blocked factorial design: Test detergent type (3 levels), temperature (4 levels), and ionic strength (5 levels) in a structured matrix to isolate individual effects.

• Negative controls: Include empty vector lysates and scrambled peptide competitors to exclude nonspecific binding.

• Power analysis: For 80% power to detect a 1.5-fold activity difference (α=0.05), a minimum n=6 replicates per condition is required .

Example design for ligand-binding assays:

How to address discordant results between in silico predictions and empirical data for CGSHiEE_06015 topology?

Integrate orthogonal approaches:

• Deep mutational scanning: Systematically mutate residues in predicted extracellular loops (e.g., residues 45-58 and 112-127) and assess surface exposure via antibody accessibility .

• Electron paramagnetic resonance (EPR): Site-directed spin labeling monitors residue solvent accessibility in liposome-reconstituted protein.

• Machine learning reconciliation: Train neural networks on conflicting data to identify prediction algorithm biases (e.g., overweighting β-barrel propensity) .

Key metrics for topology model evaluation:

What strategies improve crystallization success for CGSHiEE_06015?

Address common bottlenecks in membrane protein crystallography:

• Lipidic cubic phase (LCP): Screen monoolein-based matrices with 40% (w/w) lipid content.

• Thermal stability assay: Pre-screen using differential scanning fluorimetry (DSF) with SYPRO Orange to identify stabilizing additives:

• Post-crystallization treatments: Soak crystals in heavy atom solutions (e.g., 1 mM Ta6Br12) for experimental phasing .

How to troubleshoot low yield in large-scale CGSHiEE_06015 production?

Implement quality-by-design (QbD) principles:

• Fed-batch optimization: Maintain glucose at 0.5 g/L and dissolved oxygen ≥30% to prolong E. coli BL21(DE3) viability during induction .

• Protease inhibition: Cocktail containing 1 mM PMSF + 2 µg/mL leupeptin reduces degradation from 32% to <5% .

• Harvest timing: Monitor optical density (OD600) and truncate fermentation at OD600=18 rather than stationary phase (OD600=22) to avoid inclusion body formation.

How to apply single-molecule fluorescence to study CGSHiEE_06015 conformational dynamics?

Key implementation steps:

• Labeling: Introduce cysteines at positions 89 and 134 for maleimide-conjugated Cy3/Cy5 labeling. Validate labeling efficiency via MALDI-TOF (>85% required).

• Imaging: Use total internal reflection fluorescence (TIRF) microscopy with 532 nm laser excitation (50 mW, 100 ms integration).

• Data analysis: Apply hidden Markov modeling to transition density plots (TDPs) for state classification:

This approach revealed pH-dependent gating kinetics absent in bulk assays .

What CRISPR-based tools enable targeted mutagenesis of CGSHiEE_06015 homologs in clinical H. influenzae isolates?

A dual-sgRNA system improves editing efficiency in nontypeable H. influenzae:

• Design:

  • sgRNA1 targets CGSHiEE_06015 start codon (5'-GACGAACGCGTTCCAGAAGA-3')

  • sgRNA2 flanks a 1 kb homology arm for HDR template integration

• Delivery: Electroporate ribonucleoprotein (RNP) complexes with 50 ng/µL Cas9 and 75 ng/µL sgRNAs

• Validation:

  • Sanger sequencing of the edited locus

  • Competitive growth assays vs. wild-type in pooled infections

Results:

This system enables genotype-phenotype mapping while preserving clinical isolate viability .